Scinai Immunotherapeutics Ltd. (SCNI)Healthcare | Biotechnology | Jerusalem, Israel | NasdaqCM
0.56 USD
-0.05
(-7.500%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.56 +0.00 (0.505%) ⇧ (April 17, 2026, 7:11 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 1:38 p.m. EDT
SCNI presents a highly volatile and risky short-term investment opportunity due to its recent price declines and the Nasdaq minimum bid price deficiency. The stock has been trading below $1, with a 52-week low of $0.55, indicating significant downward pressure. The negative fundamentals, including a trailing PE of infinity, negative return on assets, and negative operating margins, suggest poor financial health. While the recent news about the acquisition of Recipharm Israel and growth prospects may offer some optimism, the stock's current price and fundamentals do not support a positive short-term outlook. Long-term investment is not advisable given the lack of consistent dividends, weak financial metrics, and overall uncertainty in the company's future. The stock's low price and high volatility make it a poor candidate for both short-term trading and long-term holding. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.133724 |
| AutoARIMA | 0.176637 |
| AutoETS | 0.176640 |
| MSTL | 0.183721 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.489 |
| Excess Kurtosis | -0.86 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 27.977 |
| Revenue per Share | 0.561 |
| Market Cap | 1,962,196 |
| Trailing P/E | Infinity |
| Beta | 1.99 |
| Previous Name | BiondVax Pharmaceuticals Ltd. |
| Website | https://www.scinai.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7292683 |
| Address1 | Jerusalem BioPark |
| Address2 | 2nd floor Hadassah Ein Kerem Campus |
| All Time High | 6,200.0 |
| All Time Low | 0.541 |
| Ask | 0.715 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 31,110 |
| Average Daily Volume3 Month | 53,464 |
| Average Volume | 53,464 |
| Average Volume10Days | 31,110 |
| Beta | 1.985 |
| Bid | 0.4352 |
| Bid Size | 2 |
| Book Value | 0.714 |
| City | Jerusalem |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.555 |
| Current Ratio | 1.296 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.6298 |
| Day Low | 0.5406 |
| Debt To Equity | 27.977 |
| Display Name | Scinai Immunotherapeutics |
| Ebitda | -6,121,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1,258.894 |
| Enterprise To Revenue | 5,877.721 |
| Enterprise Value | 7,705,692,672 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 930 2531 |
| Fifty Day Average | 0.71232 |
| Fifty Day Average Change | -0.15732002 |
| Fifty Day Average Change Percent | -0.22085582 |
| Fifty Two Week Change Percent | -72.926834 |
| Fifty Two Week High | 6.18 |
| Fifty Two Week High Change | -5.625 |
| Fifty Two Week High Change Percent | -0.9101942 |
| Fifty Two Week Low | 0.5406 |
| Fifty Two Week Low Change | 0.014400005 |
| Fifty Two Week Low Change Percent | 0.02663708 |
| Fifty Two Week Range | 0.5406 - 6.18 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,431,351,000,000 |
| Float Shares | 12,208,984,374 |
| Free Cashflow | -3,329,125 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -2.0228798 |
| Gross Profits | -2,652,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.113649994 |
| Held Percent Institutions | 0.05135 |
| Implied Shares Outstanding | 3,535,489 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,716,249,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Scinai Immunotherapeutics Ltd., a biopharmaceutical company, focuses on developing, manufacturing, and commercializing inflammation and immunology biological products for the treatment of infectious and autoimmune diseases in Israel. It develops nanosized VHH antibodies (nanoAbs) targeting diseases with unmet medical needs; and PC111, a monoclonal antibody for treating pemphigus, steven johnson's syndrome, and toxic epidermal necrolysis. The company also provides contract development and manufacturing organization services to biotech companies. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody. The company has a strategic collaboration with Recipharm Israel Ltd for the development of Lifecycle CDMO Platform. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. |
| Long Name | Scinai Immunotherapeutics Ltd. |
| Market | us_market |
| Market Cap | 1,962,196 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_9300995 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -8,307,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,014,875 |
| Open | 0.6142 |
| Operating Cashflow | -6,031,000 |
| Operating Margins | -7.0241604 |
| Payout Ratio | 0.0 |
| Phone | 972 8 930 2529 |
| Post Market Change | 0.0027999878 |
| Post Market Change Percent | 0.5045023 |
| Post Market Price | 0.5578 |
| Post Market Time | 1,776,467,517 |
| Prev Name | BiondVax Pharmaceuticals Ltd. |
| Previous Close | 0.6 |
| Price Hint | 4 |
| Price To Book | 0.77731097 |
| Price To Sales Trailing12 Months | 1.496717 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.154 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.045 |
| Regular Market Change Percent | -7.5 |
| Regular Market Day High | 0.6298 |
| Regular Market Day Low | 0.5406 |
| Regular Market Day Range | 0.5406 - 0.6298 |
| Regular Market Open | 0.6142 |
| Regular Market Previous Close | 0.6 |
| Regular Market Price | 0.555 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 69,372 |
| Return On Assets | -0.37599 |
| Return On Equity | -0.91892 |
| Revenue Growth | 0.306 |
| Revenue Per Share | 0.561 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 3,535,489 |
| Shares Percent Shares Out | 0.0235 |
| Shares Short | 83,124 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 46,346 |
| Short Name | Scinai Immunotherapeutics Ltd. |
| Short Percent Of Float | 0.023699999 |
| Short Ratio | 1.85 |
| Source Interval | 15 |
| Symbol | SCNI |
| Total Cash | 1,661,000 |
| Total Cash Per Share | 0.0 |
| Total Debt | 2,267,000 |
| Total Revenue | 1,311,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.190225 |
| Two Hundred Day Average Change | -0.635225 |
| Two Hundred Day Average Change Percent | -0.5337016 |
| Type Disp | Equity |
| Volume | 69,372 |
| Website | https://www.scinai.com |